ibrolipim
Sign in to saveIbrolipim (NO-1886) is a cholesterol lowering drug from the statin family, which acts as a lipoprotein lipase activator. The discovery of the "statin" mevalonic acid synthesis inhibitors focused new attention on control of blood lipid levels as a measure to stave off heart disease. A number of compounds have been found that treat elevated lipid levels by other diverse mechanisms. The phosphonic acid derivative ibrolipim is believed to lower those levels by accelerating fatty acid oxidation.
Research
55 papers- Ibrolipim attenuates early-stage nephropathy in diet-induced diabetic minipigs: Focus on oxidative stress and fibrogenesis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020
- Ibrolipim increases ABCA1/G1 expression by the LXRα signaling pathway in THP-1 macrophage-derived foam cells.Acta pharmacologica Sinica · 2010
- Ibrolipim attenuates high glucose-induced endothelial dysfunction in cultured human umbilical vein endothelial cells via PI3K/Akt pathway.Die Pharmazie · 2011
- [Lipid-lowering drugs].Nihon yakurigaku zasshi. Folia pharmacologica Japonica · 2001
- Bioinformatic analysis identifies LPL as a critical gene in diabetic kidney disease via lipoprotein metabolism.Frontiers in endocrinology · 2025
via PubMed
~1 min read
Encyclopedic overview
1 sectionsContents
- References
{{Chembox | Verifiedfields = changed | verifiedrevid = 461775154 | ImageFile = Ibrolipim structure.svg | ImageClass = skin-invert-image | ImageSize = 120 | PIN = Diethyl ({4-[(4-bromo-2-cyanophenyl)carbamoyl]phenyl}methyl)phosphonate | OtherNames = |Section1= |Section2= |Section3= }}
Ibrolipim (NO-1886) is a cholesterol lowering drug from the statin family, which acts as a lipoprotein lipase activator. The discovery of the "statin" mevalonic acid synthesis inhibitors focused new attention on control of blood lipid levels as a measure to stave off heart disease. A number of compounds have been found that treat elevated lipid levels by other diverse mechanisms. The phosphonic acid derivative ibrolipim is believed to lower those levels by accelerating fatty acid oxidation.
Excerpted from Wikipedia’s “ibrolipim” article, available under the CC BY-SA 4.0 licence.